China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds ...

Urogen Pharma Ltd. plans to launch its new product July 1 after the firm overcame a decidedly mixed FDA advisory panel meeting to nail down approval June 12 of Zusduri (mitomycin, formerly known as ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

WuXi AppTec (HK: 2359) and WuXi Biologics (HK: 2269) rose 4% and 3.5%, respectively, in Hong Kong trade, extending gains into ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

US factory activity contracted in May for a third consecutive month and a gauge of imports fell to a 16-year low as firms ...